What is HC Wainwright's Estimate for MNPR FY2027 Earnings?

Key Points

• HC Wainwright has revised its FY2027 earnings per share (EPS) estimate for Monopar Therapeutics to ($1.26), an improvement from the previous estimate of ($1.34).
• The firm currently holds a Buy rating on Monopar Therapeutics with a price target of $105.00.
• Insider transactions reveal significant sales, with CEO Chandler Robinson selling 16,800 shares, reducing his stake by 18.61%, and insiders having sold a total of 592,733 shares recently.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at HC Wainwright increased their FY2027 EPS estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Monday, September 29th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.26) for the year, up from their previous estimate of ($1.34). HC Wainwright currently has a "Buy" rating and a $105.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics' FY2028 earnings at ($0.37) EPS and FY2029 earnings at $0.28 EPS.

A number of other equities analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. Oppenheimer began coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 target price on the stock. Raymond James Financial initiated coverage on shares of Monopar Therapeutics in a report on Tuesday, September 2nd. They set a "strong-buy" rating and a $80.00 price target for the company. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They set a "buy" rating and a $106.00 price target for the company. Finally, BTIG Research raised their price target on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $86.22.

Monopar Therapeutics Trading Up 7.6%

NASDAQ MNPR opened at $81.67 on Wednesday. The firm has a market cap of $503.90 million, a PE ratio of -24.53 and a beta of 1.20. Monopar Therapeutics has a 1-year low of $4.50 and a 1-year high of $81.89. The stock has a 50-day moving average of $45.78 and a 200-day moving average of $40.11.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director owned 5,173 shares in the company, valued at $206,920. This trade represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 592,733 shares of company stock worth $36,700,227. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds have recently made changes to their positions in MNPR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Monopar Therapeutics in the second quarter worth $80,000. Affinity Asset Advisors LLC boosted its holdings in shares of Monopar Therapeutics by 8.9% during the 2nd quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company's stock valued at $2,415,000 after buying an additional 5,500 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Monopar Therapeutics in the 2nd quarter worth about $104,000. Rhumbline Advisers bought a new position in shares of Monopar Therapeutics in the 2nd quarter worth about $209,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after acquiring an additional 1,821 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.